Luis Borges is Chief Scientific Officer at Century Therapeutics where he leads the research and development of genetically engineered iPSCs-derived immune cell products for the treatment of cancer. Century is committed to developing novel off-the-shelf cell products that overcome the limitations of first-generation CAR-cell therapies and expand patient access to innovative cell therapies. Before joining Century, Luis was CSO at Cell Medica where he led the development of allogeneic CAR-NKT cell therapies. Prior to joining Cell Medica, Luis served as SVP of Research at Five Prime Therapeutics, where he oversaw the transition of the company into cancer immunotherapy. Before joining Five Prime, Luis worked at positions of increased responsibility at Immunex and Amgen where he led numerous drug development teams. He received his PhD from the University of Washington, Seattle in 1995.